Donate
Email Sign Up
Search

Search
Twitter
Facebook
YouTube

About Us
Alzheimer's Disease
Research
Events & Conferences
News
Ways To Give

OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Year Awarded

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Clear

Organization Type

Academic/Nonprofit

Biotechnology/For Profit

Clear

Program

Biomarkers

Clinical

Conferences/Other

Drug Discovery

Prevention

Clear

Target

Abeta

APOE

Calcium Regulation

Endocrinology

Epigenetics

Growth Factors/Neurotrophic Factors

Mitochondria/Metabolic Function

Neuroinflammation

Neuronal Degeneration

Neuronal Regeneration and Repair

Oxidative Stress

Proteostasis

Synaptic Activity and Neurotransmitters

Synuclein

Systemic Inflammation

Tau

TDP-43

Vascular

Other

Clear

Therapeutic Stage

High Throughput Screening

Hit Identification

Lead Optimization

ADME and PK

In Vivo Efficacy

Drug Manufacture - Synthesis and Formulation

IND-Enabling Safety Pharmacology and Toxicology

Clinical Phase 0

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Clinical Phase 4

Clinical Trial Design and Implementation Resources

Epidemiology

Other

Clear

Biomarker Type

Blood

Computerized Cognitive Testing

CSF

Digital

Multimodal

Neuroimaging

Ocular

Saliva

Urine

Other

Clear

Status

Active

Closed

Clear

Clear All Filters

Filters:

Export Results

796 Projects | 547 Researchers | $374,416,329 Invested

Newest
Oldest

2025

Emory University

Thomas Kukar, PhD

Development of a granulin biologic to treat progranulin deficient FTD.

Funding Amount: $349,890
Organization Type: Academic/Nonprofit
Program: Drug Discovery
Target: Proteostasis
Status: Active

2025

Circular Genomics Inc

Nikolaos Mellios, MD, PhD

Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers

Funding Amount: $250,000
Organization Type:
Program: Diagnostics Accelerator
Status: Active

2025

University of Gothenburg

Henrik Zetterberg, MD, PhD

Quality control (QC) program for CSF and plasma biomarkers for Alzheimer’s disease

Funding Amount: $1,999,997
Organization Type:
Program: Diagnostics Accelerator
Status: Active

2025

Sunbird Bio

Mario Morken, MS/MBA

Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state